<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002121</url>
  </required_header>
  <id_info>
    <org_study_id>223A</org_study_id>
    <nct_id>NCT00002121</nct_id>
  </id_info>
  <brief_title>Diethylhomospermine (DEHSPM) for Refractory AIDS-Related Diarrhea</brief_title>
  <official_title>Diethylhomospermine (DEHSPM) for Refractory AIDS-Related Diarrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Medical Center-Gainesville</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To perform preliminary clinical testing of diethylhomospermine (DEHSPM), a polyamine&#xD;
      analogue, for refractory AIDS-related diarrhea.&#xD;
&#xD;
      Possibly, DEHSPM will reduce stool volume and frequency in patients with refractory&#xD;
      AIDS-related diarrhea.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Possibly, DEHSPM will reduce stool volume and frequency in patients with refractory&#xD;
      AIDS-related diarrhea.&#xD;
&#xD;
      Patients are initially hydrated for 24 hours, followed by a 3-day baseline period. They then&#xD;
      receive intravenous infusions of DEHSPM three times per day for 3 days, followed by&#xD;
      observation for 3 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Diarrhea</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diethylhomospermine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  ARC or AIDS by CDC criteria.&#xD;
&#xD;
          -  Uncontrolled diarrhea unresponsive to high-dose, nonspecific antidiarrheal therapy.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Known idiopathic ulcerative colitis or Crohn colitis.&#xD;
&#xD;
          -  Acute stool-culture-positive bacterial colitis.&#xD;
&#xD;
          -  Acute amoebic colitis.&#xD;
&#xD;
          -  Pseudomembranous colitis with Clostridium difficile toxin positivity.&#xD;
&#xD;
          -  Short-gut syndrome.&#xD;
&#xD;
          -  Chronic pancreatitis.&#xD;
&#xD;
          -  Ischemic bowel disease.&#xD;
&#xD;
          -  Enteroenteric fistulae.&#xD;
&#xD;
          -  Other gastrointestinal tract disorders known to cause diarrhea.&#xD;
&#xD;
          -  Underlying evidence of immunosuppression other than that related to HIV infection.&#xD;
&#xD;
          -  Unable or unwilling to have subcutaneous injections.&#xD;
&#xD;
          -  Clinically significant CNS, hepatic, or renal disease.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other experimental antidiarrheal drugs.&#xD;
&#xD;
          -  Antibiotic therapy.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other experimental drugs within 1 month prior to study entry.&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  At least 2 weeks of prior high-dose, nonspecific antidiarrheal therapy (i.e.,&#xD;
             loperamide, diphenoxylate hydrochloride-atropine sulfate, or opiates) at maximally&#xD;
             tolerable doses.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gainesville Veterans Administration Med Ctr</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 1996</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Antidiarrheals</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>N(1),N(14)-bis(ethyl)homospermine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

